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SUMMARY 
Background 
Neuroendocrine tumours (NETs) of the stomach and duodenum are rare, but are increasing 
in incidence. Optimal management of localised, low grade gastric and duodenal NETs remains 
controversial.  
 
Aims 
To systematically review recent literature that has evaluated the management of localised 
low grade gastric and duodenal neuroendocrine tumours. 
 
Methods 
A systematic literature search was conducted. Articles were screened and eligible articles 
fully assessed. Additional articles were identified through the included articles’ reference 
lists. 
 
Results 
Several relevant retrospective case series were identified, but there was considerable 
heterogeneity between studies and they reported a variety of parameters. Type I gastric 
NETs had an excellent prognosis and conservative management approaches such as 
endoscopic surveillance/resection were appropriate in most cases. Many type III gastric NETs 
were low grade and appeared to have a better prognosis than has previously been 
appreciated. Endoscopic rather than surgical resection was therefore effective in some 
patients who had small, low grade tumours. Duodenal NETs were more heterogenous. 
Endoscopic resection was generally safe and effective in patients who had small, low grade, 
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non-functional, non-ampullary tumours. However some patients, especially those with larger 
or ampullary duodenal NETs, required surgical resection. 
 
Conclusions 
Most type I gastric NETs behave indolently and surgical resection is only rarely indicated. 
Some type III gastric and duodenal NETs have a worse prognosis, but selected patients who 
have small, localised, non-functional, low grade tumours are adequately and safely treated by 
endoscopic resection. Due to the complexity of this area, a multidisciplinary approach to 
management is strongly recommended. 
 
Keywords 
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INTRODUCTION 
Gastroenteropancreatic neuroendocrine tumours (GEP-NETs), previously known as carcinoid 
tumours, arise from the diffuse neuroendocrine system within the gastrointestinal tract and 
pancreas1. Foregut NETs include gastric and duodenal NETs and these tumours demonstrate 
a wide range of clinical behaviours from the commoner slow growing and indolent tumours 
to the rarer highly aggressive types which can have widespread metastases at the time of 
presentation.  
GEP-NETs were previously thought to be rare, but recent evidence has suggested that they 
are increasing in both incidence and prevalence. A recent retrospective, population-based 
study using data from the US Surveillance, Epidemiology, and End Results (SEER) program 
demonstrated a 6.4 fold increase in age adjusted incidence rate between 1973 and 20122. 
Across multiple observational studies gastric and duodenal NETs account for approximately 
7% and 2% of all digestive neuroendocrine neoplasms (NENs), respectively3,4. All GEP-NENs 
have malignant potential. They are classified into NETs grade 1 (G1), grade 2 (G2) and grade 3 
and neuroendocrine carcinoma (NEC), on the basis of mitotic count, Ki-67 index and 
differentiation status5 (Table 1). Higher grade tumours are associated with an increased risk 
of angioinvasion and metastasis and often have a poorer prognosis.  
GASTRIC NEUROENDOCRINE TUMOURS 
Gastric neuroendocrine tumours (g-NETs) are subdivided into three main distinct types (Table 
2)6,7. Type I g-NETs are associated with autoimmune atrophic gastritis and hypochlorhydria 
while Type II g-NETs develop in some patients who have gastrinomas, increased gastric acid 
secretion, Zollinger-Ellison syndrome (ZES) and multiple neuroendocrine neoplasia (MEN) 
type 1. Both type I and type II g-NETs are characterised by elevated fasting serum gastrin 
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concentrations. Hypergastrinaemia exerts a proliferative effect on enterochromaffin-like 
(ECL) cells in the stomach, leading to hyperplasia and subsequently dysplasia and 
neuroendocrine tumour development. In humans (unlike some rodent animal models) the  
current evidence in support of the hypothesis that the usually milder degree of 
hypergastrinaemia that is associated with chronic proton pump inhibitor use or with 
Helicobacter pylori induced chronic atrophic gastritis also induces type I g-NET development 
is relatively weak. However, there are some strong proponents of this view and more 
research in this area is certainly warranted8. Type III g-NETs are sporadic lesions and are not 
associated with hypergastrinaemia. They tend to behave more aggressively and sometimes 
have a poorer prognosis. Due to their rarity and the lack of published data on this topic, the 
assessment and management of patients who have type II g-NETs will not be discussed 
further in this article. 
Patient assessment 
It is imperative to identify the subtype of g-NET through biochemical, histological and 
endoscopic assessment in order to provide appropriate management for the tumour. The 
algorithm shown in Figure 1 can be used for diagnostic workup.  
Clinically most g-NETs tend to be asymptomatic and many tumours are identified incidentally 
during endoscopy performed to investigate unrelated symptoms or anaemia.  Most localised 
g-NETs do not secrete hormones or peptides into the circulation and are therefore not 
usually associated with functional syndromes; they are therefore referred to as non-
functional or non-secretory tumours. 
Biochemical investigations should include measurement of fasting serum gastrin 
concentrations9. Blood tests can also be helpful for the assessment of potential autoimmune 
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atrophic gastritis and pernicious anaemia and the presence of other associated autoimmune 
disorders such as hypothyroidism10. Serum chromogranin A concentrations correlate with the 
severity of ECL-cell hyperplasia, but may not be elevated above the upper limit of the normal 
range depending on the assay being employed. 
Most type I g-NETs are multifocal (Figure 2A). Type III g-NETs are more likely to be single and 
larger (often >10mm in diameter) at the time of presentation (Figure 2B). Biopsies from 
suspected NETs as well as biopsies from the antrum and corpus of the stomach are needed 
to identify the type and grade of NET as well as the presence/absence of underlying 
pathology such as atrophic gastritis and intestinal metaplasia11. Immunohistochemical 
staining for markers of neuroendocrine differentiation such as CgA and synaptophysin are 
typical within the tumour and diffuse linear and/or micronodular ECL-cell hyperplasia may 
also be present in the unaffected background corpus mucosa (Figure 2 D,F)12-15. 
Determination of the Ki-67 proliferation index establishes the tumour grade (Figure 2E)15,16.  
Current treatment guidelines 
The most recent treatment guidelines from the European Neuroendocrine Tumour Society 
(ENETS) were updated in 2016. For localised type I g-NETs, conservative management 
strategies are preferable to surgery depending tumour size. Annual or twice yearly 
endoscopic surveillance is advocated for type I g-NETs that measure <10mm in diameter. 
Endoscopic resection is suggested for lesions >10mm in diameter and surgery involving local 
excision or partial gastrectomy should be considered if the tumour invades the muscularis 
propria and/or there is suspicion of lymph node metastases. For type III g-NETs, surgical 
treatment involving partial or total gastrectomy and lymph node dissection remains the 
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recommended treatment option for localised tumours6. The management of patients who 
have metastatic g-NETs or functional syndromes is outside the remit of this article. 
DUODENAL NEUROENDOCRINE TUMOURS 
Duodenal neuroendocrine tumours (d-NETs) are heterogeneous. They can be classified into 
functional and non-functional tumours based on clinical presentation and hormone secretion 
and include duodenal gastrinomas; duodenal somatostatinomas; duodenal gangliocytic 
paragangliomas; poorly differentiated neuroendocrine carcinomas and non-functioning d-
NETs (which do not give rise to a clinical hormonal syndrome)17. Non-functioning tumours 
represent up to 60-98% of all d-NETs and this subgroup tends to have a more favourable 
prognosis18.  
Another classification system distinguishes d-NETs based on their location into ampullary and 
non-ampullary. For reasons that are currently poorly understood, ampullary d-NETs exhibit 
more aggressive disease biology and have a different clinical, histological and 
immunohistochemical profile19-21. They tend to present at a more advanced stage with lymph 
node and/or liver metastases and are more likely to have a higher Ki-67 index and poorly 
differentiated histology. 
Patient assessment  
Similarly to g-NETs, d-NET characterisation greatly influences a patient’s treatment plan. 
Biochemical assessment should include measurement of fasting gastrin and somatostatin 
concentrations22. The site, size and multiplicity of duodenal lesions and the relationship of 
tumours to the ampulla should be clearly noted18. The tumour should be biopsied to 
establish its grade, but biopsies of the normal stomach or duodenum are not usually helpful. 
Most d-NETs are solitary lesions measuring less than 10mm in diameter (Figure 2C). 
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Endoscopic ultrasound, CT scan and 68Ga DOTA-peptide PET/CT scans are helpful to assess 
depth of d-NET invasion and the presence of local/distant metastases and should certainly be 
considered for tumours >10mm in diameter, high grade and ampullary lesions.  
Current treatment guidelines 
The current ENETS guidelines suggest surgical resection of all localised ampullary d-NETs; 
with endoscopic resection being recommended for smaller non-ampullary, non-functional 
lesions which have favourable staging6. The management of patients who have metastatic d-
NETs or functional syndromes is again outwith the remit of this article. 
AIM 
As there is currently some controversy about the relative merits of endoscopic surveillance, 
endoscopic resection and surgical resection in patients who have localised, low grade, non-
functional gastric and duodenal NETs, we aimed to conduct a systematic literature review of 
all recent studies that have included these treatment options for patients who have such 
neoplasms.  
METHODS 
A comprehensive literature search was performed through the Healthcare Databases for 
Advanced Research utilising PUBMED, MEDLINE and independently using SCOPUS. Additional 
articles were identified through the included articles’ reference lists. 
The methodology was developed from standard guidelines under the ‘Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses’ Statement23 (see Figure 2 for PRISMA 
diagram and Supplementary Tables 1 and 2 for Pubmed MESH terms). 
Inclusion and exclusion criteria 
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All relevant studies from 2000-2019 inclusive that were published in English were considered. 
Exclusion criteria were non-human studies, single case reports, small studies involving less 
than five participants and conference abstracts. We also excluded any articles which 
exclusively described the management of patients who had grade 3 NETs or NECs, functional 
or metastatic tumours. We also excluded articles which have primarily investigated the role 
of medical therapies such as CCK2 receptor antagonist drugs and somatostatin analogues in 
type I gastric NETs and refer readers to other articles on this topic24,25. Some identified 
articles included patients within their cohorts who had metastatic disease or who had 
received medical therapies such as somatostatin analogues; such studies were included but 
those aspects of the paper were not specifically considered. 
Articles were screened by reading the abstract and eligible articles were then fully assessed. 
All data were extracted independently by two reviewers (KE and NH) using a data extraction 
form. The senior author (DMP) arbitrated if required. Extracted data included, where 
available, year of publication, study design, number of participants and data relevant to all 
outcomes. No formal statistical analysis was undertaken owing to the small number of 
eligible studies, the heterogeneity of the data presented and the fact that many studies did 
not describe important information such as tumour grade for all patients. 
RESULTS 
Type I gastric NETs 
Twenty-three non-randomised retrospective studies involving 1094 participants with type I g-
NETs were identified and included in this review. Patient demographics and tumour 
characteristics are summarised in Table 3. Most patients were diagnosed in the 5th or 6th 
decade of life and as expected a slight female predominance was noted at 58%. When 
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documented, tumours had a tendency to be multiple, located in the gastric body, small 
(maximum diameter <10mm) and low grade confirming the generally accepted type I g-NET 
characteristics. Only two cases of grade 3, type I g-NET were described, although not all 
studies included comprehensive descriptions of tumour grade. Overall, the studies 
demonstrated an indolent disease course with low disease specific mortality; specifically only 
five disease related deaths were reported across all the studies. Some studies however did 
not comment on mortality. The deaths that were described all occurred in patients who had 
unusual disease features such as a very large tumour (60mm)26, metastatic disease at the 
time of diagnosis27,28 or grade 3 histology29. Therefore, tumour related deaths seem to be 
very rare in this tumour type, and none were documented in patients who had a typical 
presentation with multifocal, small, localised, low grade neoplasms. Furthermore, the total 
local recurrence rate after resection was low but significant (74/544 patients (13.6%) in those 
studies that reported recurrence). 
Role of active surveillance in type I g-NET 
Only four studies included active surveillance as a potential management option for type I g-
NET, with the outcomes of a total of only 57 patients being described. No disease related 
mortality over a follow up of at least three years was documented. Moreover, no patients 
demonstrated tumour progression or developed metastatic disease during follow up. In all 
four studies however, the tumours had very favourable characteristics, as most of the lesions 
measured <10mm in diameter and most had low Ki-67 indices (Table 4). In the largest patient 
cohort, described by Sato et al., 25 individuals were followed up for up to 204 months with 
regular 6-12 monthly upper GI endoscopies. This study reported no disease progression or 
deaths related to disease. 
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Role of endoscopic management in type I g-NET 
Fifteen studies involving 428 patients included endoscopic resection as a potential treatment 
modality for patients with type I g-NETs. Endoscopic techniques included polypectomy, 
endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) (Table 5). 
Most of the tumours were again small and low grade with only a few studies including any 
>10mm tumours. There is therefore considerable overlap in terms of tumour characteristics 
between these patients and those who underwent endoscopic surveillance alone (as 
discussed in the preceding section and detailed in table 4). Not all studies documented the 
presence/absence of lymphovascular invasion (LVI) or lymph node (LN)/distant metastases, 
however in total four patients were noted to have LVI, five LN metastases and one distant 
metastasis. 
A range of endoscopic resection techniques were employed. Most cases appeared to involve 
polypectomy or endoscopic mucosal resection (EMR), but 76 patients underwent endoscopic 
submucosal dissections (ESDs) and in some studies the details of the resection technique 
were not provided. Some of the ESDs were however performed for very small polyps 
measuring <5mm in diameter and patients with similar polyps may simply have undergone 
endoscopic surveillance in other centres.  
Fifteen patients developed a complication (15/181, 8% in the five studies which reported this 
parameter); these included 13 cases of bleeding which was either immediate or delayed, and 
two perforations (one of which was managed endoscopically and one surgically). However, 
unfortunately the majority of studies did not describe endoscopic complication rates. Local 
tumour recurrence rates ranged from 0-63.6% depending on which series was reviewed 
(median follow up varied from 24 to 84 months) and appeared to be higher when simple 
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polypectomy using biopsy forceps or endoscopic snare was performed30. No distant 
metastases were documented during follow up and there were no deaths related to disease. 
Role of surgical management in type I g-NET 
Seven studies described the details of some patients within their cohorts who had undergone 
surgical management of type I g-NETs (Table 6). A total of 81 such patients were described. In 
some cases the tumours were larger with a maximum diameter of 45mm being recorded in 
one patient. However, this series also included several patients who had type I g-NETs that 
measured <10mm in diameter (including a few patients who even had 1-2mm tumours), in 
whom surgical resection was probably not entirely justified. Only two patients had LN 
metastases and two had distant metastases at the time of presentation. The most common 
surgical procedures were subtotal or total gastrectomy and rather surprisingly only eight 
patients were reported to have had a gastric wedge excision. All studies documented tumour 
recurrence and patient mortality rates. Although there was heterogeneity between patients 
in terms of tumour characteristics, only one death related to disease was reported in the 81 
patients (1.2%) and six local recurrences were documented during follow up periods that 
ranged from 48.5-138 months. 
Type III gastric NETs 
Ten non-randomised retrospective studies were identified that described the management of 
patients with type III g-NETs. Patient demographics, tumour characteristics and patient 
management are summarised in Table 7. 229 patients were included, of whom 63% were 
male. Most tumours were diagnosed in the 6th decade of life and the majority were solitary 
lesions. The most common tumour location in this series (when documented) was the body 
of the stomach. This cohort included 66 patients who had grade 1 and 52 who had grade 2 
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NETs, but also included 29 who had G3 NETs and 82 in whom no tumour grade was 
documented. These data suggest that in contrast to some historical cohorts, the majority of 
type III g-NETs being detected in the modern era have grade 1 or 2 histology. Nonetheless 
grade 3 tumours were still much more frequent in this tumour type than in type I g-NETs 
(Table 3).  
The main treatment administered to these patients was tumour excision. Endoscopic 
surveillance and/or palliative surgery was only offered to a very small number of patients 
who were unfit for definitive management. Eight of the studies included 121 selected 
patients who underwent endoscopic resection (EMR or ESD) for small localised tumours. 
Complete resection rates varied between 72% and 80% in most of the series, but was 87% in 
the largest series31-33. There was insufficient information to determine whether complete 
resection was more likely following ESD than EMR and ESD was only reported in 44 patients. 
In the event of incomplete tumour resection margins being identified, patients were either 
followed-up endoscopically or underwent further endoscopic treatment. Only one patient 
presented with a LN recurrence during follow up at 68 months post resection of a 16mm G1 
NET although some studies did not report tumour recurrence rates.  
Surgical treatments were described in 75 patients and included wedge resection or 
subtotal/total gastrectomy with lymphadenectomy. 87% of patients underwent a major 
surgical resection (subtotal or total gastrectomy), with wedge excision only being described 
in 10 patients. Only one patient developed liver metastases during follow up (48 months after 
wedge resection for a G3 lesion, having previously declined a total gastrectomy). 
Overall, 27 disease related deaths were documented. However nine of these patients were 
palliative at the time of presentation and did not undergo any treatment28,34, one died of 
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surgical related complications35, one from tumour bleeding35 and three more died from 
distant metastatic disease28,35. The study by Vanoli et al. described a further 13 deaths, but 
the reasons are not documented in that manuscript29. The cohort described in this paper was 
somewhat atypical however, as 61% of the type III g-NET patients had metastatic (stage III/IV) 
disease at the time of presentation, 47% tumours were >2cm in diameter and 27% had grade 
3 histology. Mortality was therefore more common in patients with type III g-NETs than type I 
g-NETs, but was only reported in approximately 12% of type-III g-NET patients in total. 
Unsurprisingly death appeared to occur more commonly in patients who had higher grade 
and more advanced stages of disease. 
Complication rates were unfortunately not documented in most studies. However in those 
studies which solely employed endoscopic management, only two cases of delayed bleeding 
were noted and both of these occurred in the ESD group32,36,37  
Duodenal NETs 
Twenty-one non-randomised retrospective studies were identified that described the 
management of patients who had d-NETs, with a total of 721 participants. Patient 
demographics, tumour characteristics, treatment modalities and the limitations of the 
studies are summarised in Table 8. There was considerable heterogeneity between the 
studies and some papers also included patients who had functioning NETs (e.g. gastrinomas 
and somatostatinomas) which are beyond the scope of this article. These studies have 
however been included as it was not always possible to extract the data from these papers 
which specifically related to the patients who had non-functional d-NETs. The median age of 
patients included in the studies ranged from 55 to 74 years and males and females appeared 
to be approximately equally represented. Most tumours were solitary and most studies 
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documented a median tumour size of approximately 10mm, although a wide range of 
diameters from 1mm to 130mm were reported. The majority of tumours (when 
documented) had grade 1 or 2 histology, with only 18 grade 3 tumours being described in 
this series. The commonest tumour location was the first part of the duodenum, but the 
series also included some patients who had ampullary d-NETs and d-NETs that were located 
in the 3rd or 4th part of the duodenum. 
Only two studies38,39 evaluated the role of endoscopic surveillance in d-NETs and these 
studies involved only 14 patients. The lesions included in these studies were small (<10mm in 
diameter) and the patients had no evidence of LN metastases. None of these patients 
demonstrated any tumour progression during follow-up (which ranged from 12-102 months).  
Thirteen papers reported surgical management of d-NETS in 320 patients. The commonest 
surgical procedure appeared to be a local excision (151/320 patients), but several patients 
also had some type of gastrectomy or pancreaticoduodenectomy (dependent on the site of 
the tumour). This cohort however included several patients who had ampullary and/or 
functional tumours. All deaths related to disease were in case series which included patients 
who had ampullary and/or functional tumours. These tumours were either metastatic at the 
time of presentation or they progressed during follow up reflecting the more aggressive 
nature of these tumours40-42. Surgical complications were documented in 66 patients, but 
most studies did not comment on this parameter. Sixty of these complications were noted in 
the paper by Margonis et al43. Unfortunately however this study did not document the exact 
complications, but recorded that 32 were minor and 28 were major according to the Clavien 
Dindo classification. 
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382 endoscopic resections were performed in total, including some that were conducted for 
multiple tumours in the same patient. A variety of techniques were employed, but the most 
common was EMR. The cohort included only six patients who underwent ESD. Endoscopic 
resection appeared to have a good safety profile and 24 complications were documented in 
the 279 procedures for which this parameter was recorded (mostly perforations or bleeding, 
with the details of all complications being shown in Table 9). Endoscopic resection techniques 
were however employed in some series only when tumours met certain criteria such as 
lesions being located in D1, of low grade and measuring <15mm in diameter. Local 
recurrence rates in these patients were also favourable, with some patients undergoing 
repeat endoscopic therapy if needed44,45. Length of follow up was comparable between 
endoscopically treated and surgical groups.  
Twenty-nine disease related deaths were documented in the various studies that were 
evaluated. These occurred in both endoscopic and surgically managed groups, however 
detailed causes of death were not recorded in most studies and it was not always possible to 
determine the treatment group in which death occurred. Only one death as a result of a 
post-surgical complication was described46.  
DISCUSSION 
Our review highlights a current lack of high-quality evidence to inform the optimal 
management of patients who have localised, low grade, non-functional gastric and duodenal 
NETs. All the studies that we identified during this systematic literature review were 
retrospective and non-randomised and did not include a standard form of reporting data 
about tumour type, size, grade, location or follow-up. No prospective clinical trials were 
identified in this field. The slow growing nature of many of these tumours means that trials 
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are difficult to perform and the optimal management strategy for individual patients can 
sometimes be difficult to establish. 
Most practice that was described within the articles that we reviewed was in broad 
agreement with the management recommendations documented in the 2016 ENETS 
guidelines for gastroduodenal NETs; however we observed trends in the published data 
which suggest that a less aggressive management approach may be appropriate in certain 
cases. 
Type I g-NETs 
As previously documented for this tumour type, the type I g-NETs that were included in this 
systematic review tended to have a very favourable prognosis with low metastatic potential 
and very few disease related deaths. Moreover, the deaths that were documented seemed 
to occur in patients who had atypical tumours at the time of diagnosis.  
Patients who had multiple lesions measuring <10mm in diameter and who had confirmed low 
grade (G1/2) histology appeared to suffer no harm as a result of receiving no specific 
treatment and simply being enrolled on an endoscopic surveillance programme. Patients who 
were managed in this way did not appear to progress after long periods of follow up and no 
disease related deaths were noted. One limitation to this conclusion however is that each of 
the published case series did not include many patients. Another possible advantage of an 
endoscopic surveillance strategy (but one which has not yet been fully explored) is that it 
may detect the gastric adenocarcinomas that are also more prevalent in this patient group at 
an earlier and potentially more treatable stage. 
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Endoscopic resection also appeared to be safe in this setting and resulted in very few life-
threatening complications. In some cases however, endoscopic resection was performed for 
very small lesions and there was considerable overlap in tumour characteristics between the 
cohorts who underwent endoscopic resection and endoscopic surveillance. The local 
recurrence rate was significant in some studies and also depended on the endoscopic 
resection method used, as simple polypectomy using biopsy forceps or snare resulted in 
>50% recurrence rates, whereas EMR and ESD appeared to be more effective, with complete 
resection rates of ~95% being reported in some series involving ESD. However, ESD did not 
appear to confer any substantial benefit in this tumour type and in general this technique can 
result in higher complication rates. The relatively high tumour recurrence rate probably 
reflects the multifocal nature of these tumours in many patients. Endoscopists should be 
aware that not all lesions may be detected at the original endoscopy. It may be impossible to 
remove all tumours and therefore EMR/ESD should probably only be used when certain 
criteria are met; these could potentially include size >10mm or possibly grade 2 histology. In 
the event of tumour recurrence or missed lesions, the studies suggested that endoscopic 
treatments could usually be safely repeated without an apparent adverse effect upon patient 
outcomes.  
In the papers included in this review, surgery was performed in some patients who had very 
small type I g-NETs. In such cases it may therefore have been unnecessary. However surgery 
did appear to be safe and effective in most of the patients in whom it was performed. In view 
of the general behaviour of type I g-NETs however, the data suggest that surgery should 
probably be reserved for larger type I g-NETs that are not suitable for endoscopic resection or 
those rare tumours which have a substantially higher grade. Even in these cases, a less 
aggressive surgical approach involving a wedge resection may be most appropriate. A 
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subtotal or total gastrectomy could however still be considered in the presence of LN 
metastases. 
Type III g-NETs 
Many of the type III NETs that were described in the papers included in this systematic review 
had low grade histology and were associated with a good prognosis, in contrast to some 
historical reports about this tumour type (see table 2 which has been adapted from the most 
recent ENETS guidelines). However, overall mortality was still substantially higher in these 
patients than in those who had type I g-NETs.  
For type III g-NETs the traditional management approach has been radical surgical resection. 
Type III g-NET patients who were treated in this way had generally good outcomes, but in 
many cases major gastric resections were performed, which are likely to have resulted in 
some long-term morbidity. Gastric wedge resections also appeared to be effective in some 
patients, but were only rarely performed, so their utility has not yet been fully established. 
Recent studies have expanded the role of endoscopic resection in a selected group of type III 
g-NET patients. The literature showed that EMR or ESD could be used with curative intent in 
small (<20mm), low grade (G1/G2) type III g-NETs where there is no evidence of LN or distant 
metastases. Although reported follow up was slightly shorter than in surgically treated 
patients, endoscopic treatment appeared to be suitable and safe in patients who had early 
lesions without compromising oncological outcomes. The data did not show any superiority 
of ESD over EMR, with the limitation that relatively few cases of ESD were performed. 
Furthermore, in the event of tumour recurrence or an increase in tumour grade, further 
endoscopic or surgical treatment appeared to be feasible without compromising oncological 
outcomes.  
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The presence of distant metastatic disease at the time of presentation was a marker of poor 
outcome and such patients should not be managed operatively. 
d-NETs 
The d-NETs identified in this systematic review were heterogeneous. For example, the largest 
series reported by Massironi40 and Margonis43 included functioning and ampullary tumours 
as well as non-functional d-NETs which made it difficult to draw conclusions. Overall, sporadic 
functional, ampullary and locally advanced d-NETs should be managed in a similar way to 
pancreatic adenocarcinoma with surgical resection being the mainstay of management. 
However, such tumours have not specifically been considered in this paper. 
In the case of small non-ampullary, grade 1, non-functional d-NETs, which generally have a 
favourable prognosis, there may be a case for endoscopic surveillance in some patients, in 
particular those who are frail or have comorbidities. However there is currently very limited 
evidence to support this approach and further studies in this area are required.  
Endoscopic resection also appears to be safe and suitable for small, low grade d-NETs with 
comparable resection rates and tumour recurrence rates to surgery. Current evidence is 
however currently insufficient to support the use of one particular resection technique. 
Although ESD is more likely to result in complete resection, it is also more likely to be 
associated with complications. Endoscopic complications occurred not infrequently in d-NET 
patients, probably reflecting the anatomy of the duodenum, but most of these complications 
seemed to be effectively treated and were not fatal. Prospective randomised clinical trials to 
clarify the role of endoscopic resection and resection technique in d-NETs would however be 
helpful. 
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Conclusions 
The quality of the data that currently informs management decisions in patients who have 
localised low grade gastric and duodenal NETs is very low. Evidence from a number of 
retrospective case series does however seem to suggest that less aggressive treatment 
approaches such as endoscopic surveillance or endoscopic resection with close follow up are 
safe and effective in many patients, especially those who have type I g-NETs. Similar 
approaches also appear to be appropriate in selected patients who have small, low grade, 
non-ampullary d-NETs. Type III g-NETs are potentially more serious and these tumours should 
therefore generally be resected unless they are metastatic. However some type III g-NET 
patients appear to be suitable for endoscopic resection or gastric wedge excision rather than 
needing to undergo a major gastric resection. Based on our findings and bearing in mind the 
weak level of evidence currently available, we have made some suggestions about the 
management of patients with localised type I g-NETs in Figure 4. However we feel that the 
evidence is currently insufficient to suggest similar algorithms for the management of type III 
g-NETs and d-NETs. 
Prospective clinical trials or possibly large multi-centre registries with prospective detailed 
recording of patient/tumour characteristics and outcomes are however desperately needed 
to better inform the management of patients who have localised, low grade, non-functional 
g-NETs and d-NETs. Such studies will hopefully in future provide data that will permit 
personalisation of management approaches in this patient group. 
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FIGURE LEGENDS 
Figure 1: Diagnostic algorithm for suspected g-NET. Patient assessment should include 
endoscopic, biochemical, histological as well as clinical assessment. All cases should be 
referred to specialist NET centre and discussed at a Multidisciplinary Team meeting for 
further management. 
Figure 2: Endoscopic images of (A) Multiple type 1 g-NETs, (B) Solitary type III g-NET and (C) 
Solitary d-NET. Histological images demonstrating (D) Synaptophysin immunohistochemistry 
of type I g-NET, (E) Ki67 immunohistochemistry of same grade 1 type I g-NET and (F) 
Synaptophysin immunohistochemistry of atrophic gastric mucosa from same patient with 
type I g-NET demonstrating linear and nodular ECL cell hyperplasia. 
Figure 3: PRISMA diagram depicting selection criteria for inclusion of articles for gastric and 
duodenal NETs. 
Figure 4: Proposed management algorithm for patients with localised type-1 g-NETs. 
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TABLES AND FIGURES 
Table 1: World Health Organisation classification and grading for neuroendocrine neoplasms 
(NENs) of the GI tract and hepatopancreatobiliary organs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Terminology Differentiation Grade Mitotic rate* 
(mitoses/2 mm2) 
Ki-67% 
index* 
NET, G1 
Well differentiated 
Low <2 <3% 
NET, G2 Intermediate 2–20 3–20% 
NET, G3 High >20 >20% 
NEC, small‐cell type 
(SCNEC) 
Poorly differentiated 
High† >20 >20% 
NEC, large‐cell type 
(LCNEC) 
>20 >20% 
MiNEN Well or poorly 
differentiated‡ 
Variable‡ Variable‡ Variable‡ 
LCNEC, Large‐cell neuroendocrine carcinoma; MiNEN, Mixed neuroendocrine–non‐neuroendocrine neoplasm; NEC, Neuroendocrine 
carcinoma; NET, Neuroendocrine tumour; SCNEC, Small‐cell neuroendocrine carcinoma. 
* Mitotic rates are to be expressed as the number of mitoses/2 mm2 as determined by counting in 50 fields of 0.2 mm2 (i.e. in a total 
area of 10 mm2); the Ki‐67 proliferation index value is determined by counting at least 500 cells in the regions of highest labelling 
(hot‐spots), which are identified at scanning magnification; the final grade is based on whichever of the two proliferation indexes 
places the neoplasm in the higher‐grade category. 
† Poorly differentiated NECs are not formally graded but are considered high‐grade by definition. 
‡ In most MiNENs, both the neuroendocrine and non‐neuroendocrine components are poorly differentiated, and the neuroendocrine 
component has proliferation indices in the same range as other NECs, but this conceptual category allows for the possibility that one 
or both components may be well differentiated; when feasible, each component should therefore be graded separately. 
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Table 2: Classification of gastric neuroendocrine tumours according to type and general 
characteristics in endoscopic appearance, histology and prognostic indicators. 
  Type I Type II Type III   
Proportion, % 70–80 5–10 15-20   
Gastric localisation Corpus, fundus Corpus, fundus, antrum Antrum or corpus   
Typical endoscopic and 
morphological 
characteristics 
Often multiple (>60%), 
small (<1 cm); polypoid or 
submucosal 
Often multiple, small 
(<1–2 cm); polypoid 
(sessile) 
Single, large size 
(>2 cm); occasionally 
ulcerated 
  
Associated disorders 
Chronic atrophic gastritis 
and pernicious anaemia 
Gastrinoma/Multiple 
endocrine neoplasia 1 
Sporadic   
Histology 
Well differentiated 
(G1-G2) 
Well differentiated 
(G1-G2) 
Well differentiated, 
poorly differentiated 
or mixed 
endo/exocrine 
(G1,2,3 NET or NEC) 
  
Fasting serum gastrin 
concentrations 
↑ ↑ Normal   
Gastric pH ↑↑ ↓ Normal   
Risk of metastases (%) 2–5 10–30 50–100   
Prognosis Excellent Very good Poor   
†Adapted from ENETS Consensus Guidelines
6
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Table 3: Patient and tumour characteristics of all studies describing Type I g-NETs including treatment methods. 
Study n 
Sex 
(M:F) 
Age 
(Median†, Mean‡) 
Multiple lesions 
n (%) 
Size mm 
(Median†, Mean‡) 
Grade 
(G1/G2/G3/
UK) 
Location 
(F/B/A/UK or O) 
Endoscopic 
Surveillance 
Endoscopic 
Treatment 
Surgery 
Follow up 
months 
(Median†, Mean‡) 
Death/ 
Death 
related to disease 
Local 
Recurrence 
Chung et al47, 
2018 
142 50:92 60.8‡(SD±14.3) 103(72.5) 14 ‡(SD±18) 89/26/0/27 9/93/17/23 - X X 32.4‡(SD±30) - - 
Vanoli et al29, 
2018 
123 45:78 64† 67(54) 4† (IQR:2-8) 111/11/1/0 0/117/6/0 - 79/123 44/123 
87† 
(R:52-146) 
0/1 - 
Manfredi et al33, 
2017 
84 30:54 55.8†(R:9.6-84.8) 30(36) 20†(R:2-45) 43/14/1/26 - - 64/69§ 4/69§ 
48† 
(R:0-543.6) 
- - 
Campana et al48, 
2016 
97# 38:59 59 ‡ 97(100) 5† 56/33/0/8 0/97/0/0 13/97 45/97 3/97 
30.5† 
(IQR: 12-64) 
0 16 
Sagatun et al27, 
2016 
26# 7:19 59.5‡ 19(73) 6‡ 24/2/0/0 - 8/26 - 8/26 34† 6/1 - 
Lee et al49, 2016 17 7:10 57.5 ‡(SD±14.9) - 9‡(SD±6) 5/12/0/0 - - X X 14†(R:0-147) - 0 
Chen et al50, 
2015 
56# 11:45 63.3†(R:37.2-89.4) 31(55) 3 †(R:0.8-25) 47/9/0/0 13/34/9/0 - 16/56 26/56 62.4†(R:2-205) 2/0 - 
Sato et al51, 2014 82 44:38 56†(R:24-79) 38(46) 5 †(R:1-45) - 11/70/0/1 25/82 41/82 16/82 84†(R:0-240) 0 2 
Kim et al52, 2014 62 37:25 50†(R:40-68) - 7.6 ‡(SD±4.1) 72/15/0/0¶ 9/60/18/0¶  62/62 - - - - 
Uygun et al53, 
2014 
22 11:11 51†(R:36-67) 17(77) 
18 pts:<10, 
4 pts:10-20 
All lesions 
Ki 67<12% 
- - 22/22 - 84†(R:24-168) - 4 
Louthan et al34, 
2014 
18 4:14 60†(R:41-74) - - 16/2/0/0 2/13/3/0 - 17/18 1/18 46.8†(R:6-204) 1/0 - 
Thomas et al54, 
2013 
111 29:82 
58.5‡ (R:29-84, 
SD±12.7) 
53(48) 
7.9‡ (R:0.2-100 
SD±12.1) 
85/9/0/17 - - 59/111 20/111 76†(R:12-384) 2/0 22 
Merola et al30, 
2012 
33 9:24 65†(R:23-81) 17(52) 5†(R:2-20) - - - 33/33 - 46†(R:4-123) 0 21 
Chen et al37, 
2012 
15 5:10 48†(R:35-70) 5(33) 4.5†(R:2-8) 15/0/0/0 3/7/0/5 - 15/15 - 28‡(R:7-44) 0 2 
Li et al36, 2012 11 4:7 48‡(R:35-56) 2(18) 4.5†(R:3-6) 11/0/0/0 2/9/0/0 - 11/11  24†(R:12-40) 0 1 
Endo et al35, 
2012 
10 6:4 62.5†(R:54-72) 2(20) 5†(R:1-7) 6/4/0/0 - 1/10 2/10 7/10 48.5†(R:3-83) 3/0 - 
Kim et al26, 2010 22# 13:9 52.6†(R:32-71) 2(9) 
15.9† 
(SD±12.8) 
- 10/9/3/0 - 13/22 5/22 
68‡ 
(SD±45) 
0/1 2 
Gladdy et al55, 
2009 
65 11:54 58†(R:29-91) 53(82) 
ES:5† (SD±1) 
SR:13†(SD±3) 
- - - 46/65 19/65 
ET 25†(R:1-157) 
SR:60†(R:1-176) 
0 3 
Safatle-Ribeiro 
et al28, 2007 
13# 4:9 62‡(R:45-79) 12(92) 
7 pts:<10 
5pys: 10-20 
9/4/0/0 0/13/0/0 - 6/13 6/13 36†(R:7-107) 5/1 0 
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1pt:>20 
Ravizza et al56, 
2007 
11 6:5 61‡(R:45-72) 7(64) all lesions<10 - 0/11/0/0 11/11 - - 54†(R:9-136) 0 - 
Dakin et al57, 
2006 
18# 6:12 52‡(SD±11.6) 4(22) - - - - - 10/18 - - - 
Borch et al58, 
2005 
51 13:38 66‡(R:39-86) 34(67) 10†(R:4-80) - - 3/51 26/51 22/51 65†(R:14-215) 20/1 1 
Okada et al59, 
2005 
5 1:4 
52.6‡(R:42-62, 
SD± 7.5) 
5(100) 
5† (R:3-15 
SD±4.9) 
- - - - 5/5 108.4†(R:4-144) 0 0 
G1: Grade 1; G2: Grade 2; G3: Grade 3; F: fundus; B: body; A: antrum; -: data not reported in manuscript; UK: unknown; §: Treatment data available on 69 pts only; ¶: multiple tumours recorded; X: studies where details could not 
be extracted but did include this treatment option; #: Campana et al: 36 pts treated with somatostatin analogue (SSA); Sagatun et al: 10 pts treated with SSA; Chen et al: 30 patients treated with SSA; Thomas et al: 32 pts treated 
with SSA; Kim et al: 4 pts not treated due to either advanced disease or other malignancy; Safatle-Ribeiro et al: 1pt not treated due to advanced disease; Dakin et al: 8 pts treated with SSA 
 
Table 4: Studies describing endoscopic surveillance in Type I g-NETs. 
Study n 
Sex 
(M:F) 
Age 
(Median†, Mean‡) 
Multiple lesions n 
(%) 
Size mm 
(Median†, Mean‡) 
Grade 
(G1/G2/G3/UK) 
Location 
(F/B/A) 
Depth of invasion 
(M/SM/MP/S/UK) 
Follow up months 
(Median†, Mean‡) 
Death/ 
Death related to 
disease 
Recurrence 
(local/distant metastasis) 
Campana et 
al48, 2016 
13 6:7 62†(IQR:50-65) 
2pts<5 lesions, 
11pts>5 lesions 
(100) 
4.5†(IQR:3-10) 3/8/0/2 - - 82†(IQR:34-120) 0 0 
Sagatun et 
al27, 2016 
8 - 57.9‡(SEM:4.2) 8 (100) 5‡ 8/0/0/0 - 0/0/0/0/8 34† 1/0 - 
Sato et al51, 
2014 
25 9:16 54†(R:24-79) 16 (64) 4†(R:2-13) 0/0/0/25 - 4/3/0/0/18 84†(R:0-204) 0 0 
Ravizza et 
al56, 2007 
11 6:5 61‡(R:45-72) 7 (64) all lesions<10 Ki-67:2.5%† 0/11/0 - 54†(R:9-136) 0 0 
G1: grade 1; G2: grade 2; G3: grade 3; F: fundus; B: body; A: antrum; -: data not reported in manuscript; UK: unknown; M: mucosa; SM: submucosa, MP: muscularis propria, S: serosa 
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Table 5: Studies describing tumour characteristics and follow up when utilising endoscopic treatment for Type I g-NETs. 
Study n 
Sex 
(M:F) 
Age 
(Median†, Mean‡) 
Multiple 
lesions 
n (%) 
Size mm 
(Median†, 
Mean‡) 
Grade 
(G1/G2/G3/UK) 
Location 
(F/B/A/UK or O) 
Depth of 
invasion 
(M/SM/MP/S) 
Endoscopic 
Treatment 
(Polypectomy
/EMR/ESD) 
Complications 
Follow up months 
(Median†, Mean‡) 
Death/ 
Death related 
to disease 
Local 
Recurrence 
Campana 
et al48, 
2016 
45 14:31 61†(IQR:49-71) 45 (100) 5†(IQR:3-8) 28/16/0/1 0/45/0/0 - 45§ - 30.5† (IQR: 12-64) 0 11 
Chen et 
al50, 2015 
30 - - - - - - - 30§ - - 2/0 - 
Kim et al60, 
2014 
62 37:25 50†(R:40-68) - 7.6‡(SD±4.1) 72/15/0/0¥ 9/60/18/0¥ - 87(0/48/39) 14¶ - - - 
Sato et al51, 
2014 
41 28:13 57†(R:24-79) 26(63) 5†(R:1-23) - - 10/31/0/0 41 (0/30/11) - 84†(R:0-240) 0 2 
Uygun et 
al53, 2014 
22 11:11 51†(R:36-67) 17(77) 
18pts<10 
4pts:10-20 
All lesions 
Ki 67%<12% 
- - 22 (0/22/0) 1¶ 84†(R:24-168) - 4 
Louthan et 
al34, 2014 
17 - - - - - - - 17 - 46.8†(R:6-204) 1/0 - 
Thomas et 
al54, 2013 
59 21:38 - - - 56/3/0/0 - 0/48/11/0 59 - 90.3†(SD±72.5) 2/0 5 
Merola et 
al30, 2012 
33 9:24 65†(R:23-81) 17(52) 5†(R:2-20) - - - 33 (18/15/0) - 46†(R:4-123) 0 21 
Chen et 
al37, 2012 
15 5:10 48†(R:35-70) 5(33) 4.5†(R:2-8) 15/0/0/0 3/7/0/5 5/10/0/0 15 (0/0/15) 0 28‡(R:7-44) 0 2 
Li et al36, 
2012 
11 4:7 48‡(R:35-56) 2(18) 4.5†(R:3-6) 11/0/0/0 2/9/0/0 1/10/0/0 11 (0/0/11) 0 24†(R:12-40) 0 1 
Endo et 
al35, 2012 
2 1:1 65†(R:60-70) 0 3.5†(R:1-6) 2/0/0/0 - 1/1/0/0 2 (0/2/0) - 43† (R:3-83) 1/0 0 
Kim et al26, 
2010 
13 - - - - - - - 13 - - - - 
Gladdy et 
al55, 2009 
46 39:7 59†(R:44-91) 42(91) 5†(SD±1) - - 0/46/0/0 46 0 25†(R:1-157) 0 0 
Safatle-
Ribeiro et 
al28, 2007 
6 1:5 62.5‡(R:48-83) 6(100) 
3pts<10 
3pts:10-20 
4/2/0/0 0/6/0/0 - 6 (0/6/0) - 30† (R:7-75) 3/0 0 
Borch et 
al58, 2005 
26 - - - - - - - 26 - - 1 0 
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G1: grade 1; G2: grade 2; G3: grade 3; -: data not reported in manuscript; UK: unknown; F: fundus; B: body; A:antrum; M: mucosa; SM: submucosa, MP: muscularis propria, S: serosa; EMR: endoscopic mucosal resection; ESD: 
endoscopic submucosal dissection; §: No details regarding type of endoscopic procedure; ¥: multiple tumours described in some patients; ¶: Complications: Kim et al: Bleeding - 13 all managed endoscopically (5 EMR and 8 ESD), 
Perforation - 1 (ESD); Uygun et al: 1 perforation managed surgically 
 
Table 6: Studies describing tumour characteristics and follow up during the surgical management of Type I g-NETs. 
Study n 
Sex 
(M:F) 
Age 
(Median†, 
Mean‡) 
Multiple 
lesions 
n (%) 
Size mm 
(Median†, Mean‡) 
Grade 
(G1/G2/G3) 
Location 
(F/B/A) 
Depth of invasion 
(M/SM/MP/S) 
Surgery 
(Wedge resection/ 
Antrectomy/ 
Sub or Total gastrectomy) 
Follow up months 
(Median†, Mean‡) 
Death/ 
Death related 
to disease 
Local 
Recurrence 
Sagatun et 
al27, 2016 
8 - 61.2‡(SEM:2.8) 8(100) 13.5‡(IQR:10.8) - - - 8(0/0/8) - 3/1 0 
Sato et al51, 
2014 
16 7:9 58.5†(R:39-76) 7(44) 6.5†(R:1-45) - - 5/10/1/0 16(0/4/12) 138†(R:0-228) 0 0 
Thomas et 
al54, 2013 
20 - - - 31.9 ‡(SD±32.4) - - - 20(0/2/18) - 2/0 4 
Endo et al35, 
2012 
7 5:2 65†(R:54-72) 2(29) 5†(R:1-7) 3/4/0 - 0/7/0/0 7 (1/1/5) 48.5†(R:32-82) 3/0 0 
Gladdy et 
al55, 2009 
19 4:15 58†(R:29-72) 8(42) 13†(SD±3) - - - 19(7/6/6) 60†(R:1-176) 0 2 
Safatle-
Ribeiro et 
al28, 2007 
6 2:4 55‡(R:36-75) 5(92) 
3 <10mm, 
2:10-20mm, 
1>20 mm 
4/2/0 0/6/0 - 6(0/0/6) 91†(R:10-107) 1/0 0 
Okada et 
al59, 2005 
5 1:4 
52.6‡(SD±7.5, 
R:42-62) 
5(100) 
5†(SD±4.9, 
R:3-15) 
- - 0/5/0/0 5(0/0/5) 108.4† (R:4-144) 0 0 
G1: grade 1; G2: grade 2; G3: grade 3; -: data not reported in manuscript; F: fundus; B: body; A: antrum; M: mucosa; SM: submucosa, MP: muscularis propria, S: serosa  
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Table 7: Patient and tumour characteristics, including patient management and follow up in Type III g-NETs 
Study n 
Sex 
(M:F) 
Age 
(Median†
, Mean‡) 
Solitary 
Lesions 
n (%) 
Size mm 
(Median†, 
Mean‡) 
Grade 
(G1/G2/G3/UK) 
Location 
(F/B/A/ 
UK or other) 
Depth of invasion 
(M/SM/MP/S/UK) 
Endoscopic 
Treatment 
(EMR/ESD) 
Surgery 
(Wedge 
resection/ 
Antrectomy/ 
Sub or Total 
gastrectomy) 
LVI 
Lymph 
node 
metastasis 
Distant 
metastasis 
Follow up 
months 
(Median†, 
Mean‡) 
Death / 
Death 
related 
to 
disease 
Recurrence 
Vanoli et 
al29, 2019 
34 24: 10 59† 34(100) 
20† 
(IQR:15-45) 
15/10/9/0 0/32/2/0 0/13/21/0/0 8 26 - 11 10 - -/13 - 
Min et 
al31, 2018 
32 23:9 
G1 53.5‡ 
(R:27-75) 
G2/3 
50.4‡ 
(R:36-62) 
32(100) 
G1 8‡ 
(R:2-25, SD±6) 
G2/3 15‡ 
(R:6-35, SD±9) 
25/5/2/0 0/25/7/0 0/31/1/0/0 22 (5/17) 10(7/0/3) 5 2 0 
ER 59† 
(R:6-96) 
WR:70† 
(R:58-102) 
1/0 2 
Manfredi 
et al33, 
2017 
52§ 33:19 
58† 
(R:19.3-
81.4) 
49(94) 
20† 
(R:4-160) 
10/26/0/16 - - 15 17(0/0/17) - - - 
24† 
(R:0-177.6) 
- - 
Louthan 
et al34, 
2014 
7 5:2 
66† 
(R:47-85) 
- - 0/3/4/0 4/3/0/0 - 0 1 (0/0/1) - 2 6 
46.8† 
(R:6-204) 
7/6 - 
Kwon et 
al32, 2013 
50 28:22 
58.6‡ 
(R:25-85) 
48(96) 
33pts <10mm 
17pts >10mm 
- 8/38/4/0 0/49/1/0/0 50 (41/9) 0 3 0 0 
46† 
(R:13-60) 
0/0 0 
Endo et 
al35, 2012 
12§ 9:3 
67† 
(R:46-79) 
12(100) 30†(R:8-98) 3/2/7/0 - 2/4/1/5/0 1 (1/0) 9(0/0/9) - 2 1 
28.5† 
(R:1-122) 
4/3 0 
Chen et 
al37, 2012 
10 3:7 
53.5† 
(R:40-82) 
9(90) 15†(R:5-30) 7/3/0/0 1/7/1/1 0/10/0/0/0 10 (0/10) 0 0 0 - 
27.5‡ 
(R:11-52) 
-/0 0 
Li et al36, 
2012 
8 3:5 
56‡ 
(R:35-71) 
8(100) 16.5†(R:8-30) 6/2/0/0 1/5/1/1 0/8/0/0/0 8 (0/8) 0 0 - - 
27† 
(R:14-48) 
0 0 
Kim et 
al26, 2010 
16§ 10:6 
51.1† 
(R:25-64) 
15(94) 11.7†(SD±5.1) - 8/6/2/0 0/13/1/0/2 7 7(3/0/4) - 0 0 
68‡ 
(SD±45) 
-/0 0 
Safatle-
Ribeiro et 
al28, 2007 
8§ 4:4 
60.5‡ 
(R:36-78) 
8(100) 
1pt<10mm 
1pt: 10-20mm 
6pts>20mm 
0/1/7/0 0/5/3/0 - - 5(0/0/5) - - - 
12† 
(R:6-144) 
5/5 - 
G1: grade 1; G2: grade 2; G3: grade 3; -: data not reported in manuscript; UK: unknown; F: fundus; B: body; A: antrum; M: mucosa; SM: submucosa, MP: muscularis propria, S: serosa; EMR: endoscopic mucosal resection; ESD: endoscopic submucosal 
dissection; LVI: lymphovascular invasion, §: Manfred et al: Complete treatment data reported on only 38 pts, 32 of whom underwent invasive treatment options; Endo et al: 1/12 had palliative treatment on diagnosis; Kim et al: only 14/16 patients 
underwent invasive treatment options, Safatle-Rubeiro: only 5/8 patients underwent invasive treatment options 
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Table 8: Patient and tumour characteristics, including patient management in d-NETs, including study limitations. 
Study n 
Sex 
(M:F) 
Age 
(Median†, Mean‡) 
Number of 
solitary lesions 
n (%) 
Size mm 
(Median†, Mean‡) 
Grade 
(G1/G2/G3/UK) 
Location 
(D1/D2/ampullary/
D3-4/UK) 
Endoscopic 
Surveillance 
Endoscopic 
resection 
Surgery Study Limitations 
Mahmud et 
al44, 2019 
33 21:12 57.7†(R:52.5-67.8) 33(100) 
Polypectomy 10† 
(IQR: 2-4) 
EMR† 23 (IQR:6-12) 
21/3/0/9 30/3/0/0/0 - 33/33 - Includes functioning d-NETs 
Fujimoto et 
al61, 2019 
10 7:3 55.5‡(R:39-82) 10(100) All less than <13 10/0/0/0 6/4/0/0/0 - 10/10 - All lesions <13mm 
Khara et al62, 
2019 
8 1:8 63†(R:34-79) 8(100) 6† (R:3-9) 8/0/0/0 8/0/0/0/0 - 8/8 - All lesions <10mm 
Massironi et 
al40, 2018 
108# 69:39 59.5†(R:18-87) 84(78) 12† (R:3-130) 71/21/4/12 44/24/38/0/2 - 16/108 57/108 Includes functioning d-NETs 
Park et al63, 
2018 
15 6:9 55.4‡(SD±11.6) 15(100) 6.6‡ (SD±-3.9) - 12/3/0/0/0 - 15/15 -  
Oono et al64, 
2019 
12 7:5 74†(R:55-84) 12(100) 9† (R:4-10) 11/1/0/0 11/1/0/0/0 - 12/12 - All lesions <10mm 
Hatta et al46, 
2017 
49 35:14 63.9‡(SD±8.5) 43(88) 8‡ (SD±-3.9) 49/0/0/0 46/3/0/0/0 - 35/49 14/49 
Size restriction <20mm, 
includes functional NETs 
Weatherall 
et al65, 2017 
36 17:19 60†(R:46-89) 32(89) 10† (R:4-40) 20/10/0/6 32/4/0/0/0 - 8/36 28/36 
Excludes ampullary, functional 
and high grade d-NETs 
Iwasaki et 
al66, 2017 
6 3:3 59.5†(R:41.75-63.75) 5(83) 23† (IQR:14-40.5) 4/0/1/1 0/6/0/0/0 - - 6/6  
Margonis et 
al43, 2016 
146 72:73~ 
63.2†(R:55-71 
ER:63.5†(R:52-70.8) 
LR 63.4†(R:52-70.8) 
PD 63† (R:56-70) 
- 
12†(IQR:7-20) 
ER:7†(R:4-11) 
LR 13†(R:8-17) 
PD 20†(R:9-28) 
113/13/3/17 98/0/16/9/23 - 39/146 107/146 Includes functioning d-NETs 
Scherer et 
al45, 2015 
37 - 
EBL 67.5‡ 
(SD±11.7) ER 58.3‡ 
(SD±14.5) 
35(95) 
EBL: max 6.7 
(SD±2.1) 
ER: max 6.7 
(SD±1.7) 
31/0/0/8§ 35/4/0/0/0§ - 37/37 - All lesions <10mm 
Shroff et al67, 
2015 
30 16:14 
59† (R:52.5-67.5) 
ER:58.7†(R:45-74) 
SR:58.3†(R:34-75) 
30(100) 
8.5†(R:4-19) 
ER:11.4‡(SD±-3.9) 
SR:7.7‡(SD±3.8) 
- 23/7/0/0/0 - 20/30 10/30 All lesions<20mm 
Untch et al41, 
2014 
75 46:29 60†(R:36-83) 75(100) 17‡ (SD±13) 54/7/10/4 29/37/0/5/4 - 12/75 63/75 
Includes ampullary and non-
ampullary and functioning d-
NETs 
Kim et al60, 
2014 
38 19:19 63†(R:38-79) 36(95) All less than 10 38/0/0/0 34/7/0/0/0§ - 38/38 - All lesions<10mm 
Kim et al38, 
2013 
14 8:6 61.5†(R:51.25-72) 14(100) 8† (IQR:6.25-10) 10/0/04 13/1/0/0/0 1/14 12/14 1/14  
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Min et al39, 
2013 
27 16:11 
Surv:61† (R:42-81) 
ER:55.5† (R:32-73) 
27(100) 
Surv:4† (R:1-9) 
ER:7†(R:2-10) 
- 27/0/0/0/0 13/27 14/27 - 
Surveillance offered when no 
evidence of lymph node or 
regional metastases 
Waisberg et 
al68, 2013 
20 8:12 66.4‡(R:43-88) 18(90) 11‡ (R:3-60) - 15/4/0/1/0 - 15/20 5/20 
Excludes ampullary and 
functional d-NETs 
Ishido et al69, 
2010 
11 8:3 57† 11(10) 9† (R:2-12) 11/0/0/0 9/2/0/0/0 - 3/11 8/11 
Excludes ampullary and 
functional d-NETs 
Nikou et al70, 
2010 
8 3:5 56.5†(R:47.25-66.25) 8(100) 11† (IQR:9.5-17.25) - 5/0/3/0/0 - 2/8 6/8 
Includes ampullary and non-
ampullary d-NETs 
Zyromski et 
al42, 2002 
27 15:12 66†(R:43-86) 26(100) 
ER: All less than <10 
SR: 14† (IQR:10.5-
32.5) 
- 16/7/2/2/0 - 11/26 15/26 
Includes functioning NETs and 
1 patient who had no 
treatment 
Witzigmann 
et al19, 2002 
12 9:3 55.4‡(R:41-72) 12(100) 10† (IQR:6-18.7) - 5/2/6/0/0§ - 2/12 9/12 
Includes ampullary and non-
ampullary d-NETs and 1 patient 
who had chemotherapy only 
G1: grade 1; G2: grade 2; G3: grade 3; -: data not reported in manuscript; UK: unknown; D1: 1st part of duodenum; D2: 2nd part of duodenum; D3-4: 3rd or 4th part of duodenum; §: Multiple tumours; #: Massironi et al: 35 pts 
underwent treatment with chemotherapy/PRRT/liver directed therapy; ~: 1 patient not accounted for in paper 
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Table 9: Treatment management and follow up in in d-NETs. 
Study n 
Endoscopic 
Surveillance 
Endoscopic 
Resection 
(Polypectomy/EMR/ESD/APC/EBL) 
Surgery 
(LR/S-TG/PD-
PDDD) 
LVI 
Lymph 
node 
metastasis 
Distant 
metastasis 
Endoscopic 
Complications 
Surgical 
Complications 
Follow up-months 
(Median†, Mean‡) 
Deaths/ 
Deaths related 
to disease 
Recurrence/ 
Progression 
Mahmud et 
al44, 2019 
33 0 33(10/23/0/0/0) - - 0 0 2§ - 24‡(IQR:6.5-48.6) 3/0 
Polypectomy:1 
EMR:3 
Fujimoto et 
al61, 2019 
10 0 10(0/10/0/0/0) - 3 - 0 1§ /1¶ - 18.6†(R:6-52) 0/0 0 
Khara et al62, 
2019 
8 0 8(0/0/0/0/8) - - 0 0 0 - 51.5‡(R:25.4-67) 0/0 0 
Park et al63, 
2018 
15 0 15(0/15/0/0/0) - 1 0 0 1§ / 1¶ - 26.1†(SD±20.7) 0/0 0 
Oono et al64, 
2019 
12 0 12(0/12/0/0/0) - - 0 0 1§ - 17‡(R:1-89) 0/0 0 
Scherer et 
al45, 2015 
37 0 39®(0/16/0/0/23) - 0/16 - 0 1§ /2~ - EBL:19†(SD±15.2) 0/0 2 
Kim et al60, 
2014 
38 0 37(0/37/0/0/0) - 4 0 0 5§ - 17†(R:1-53) 0/0 0 
Min et al39, 
2013 
27 13 14(0/11/0/3/0) - 0 0 0 2¶ - 
Surv:37‡ (R:10-102) 
ER:40‡(R:14-129) 
0/0 3 
Iwasaki et 
al66, 2017 
6 0 - 6 (3/3/0) 2 3 0 - - 51.6‡(R:4.8-130) 0/0 1 
Massisoni et 
al40, 2018 
73 0 16(-) 57 - 37 17 - - 76‡(R:7-211) 20/19 5 
Hatta et al46, 
2017 
49 0 35(0/29/6/0/0) 14 (5/6/3) 12 6 2 2¶ - 66.5‡(SD±48.2) 8/2 1 
Weatherall 
et al65, 2017 
36 0 8(7/1/0/0/0) 28 (25/0/3)  5/19 0 - - 25‡(R:9-139) 9/0 1 
Margonis et 
al43, 2016 
146 0 39(-) 107 (57/0/50) 18 50/85 0 2 60 28‡(IQR:6.4-52) - 26 
Shroff et al67, 
2015 
30 0 20(0/20/0/0/0) 10 (6/0/4) 1 0 0 1¶ / 1# 1¶ /1¤ /1¥ 
25.5‡(IQR:15.5-
49.25) 
0/0 5 
Untch et al41, 
2014 
75 0 12(0/12/0/0/0) 63(34/0/29) - 23/44 0 - - 27‡ -/4 11 
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Kim et al38, 
2013 
14 1 12(0/12/0/0/0) 1(0/1/0) 0 0 0 1§ - 12‡(IQR:3.25-51.5) - 0 
Waisberg et 
al68, 2013 
20 0 15(0/15/0/0/0) 5 (1/4/0) 0 - 0 - - 39.6†(R:3-96) 7/1 0 
Ishido et al69, 
2010 
11 0 3(0/3/0/0/0) 8 (4/3/1) 4 1 0 0 - 54‡(R:6-201) 0/0 0 
Nikou et al70, 
2010 
8 0 2(2/0/0/0/0) 6 (3/0/3) n- 3 1 0 - 51†(R:18-115.2) 1/0 0 
Zyromski et 
al42, 2002 
26 0 11(0/11/0/0/0) 15 (10/0/5) 2 2 - -  
ER:50.4‡(R:18-96) 
SR:51.6‡(R:18-270) 
4/3 6 
Witzigmann 
et al19, 2002 
11 0 2(0/2/0/0/0) 9 (3/1/5) - 1 1 - 1§ / 2× 68† (R:8-102) 2/0 0 
EMR: endoscopic mucosal resection; ESD: endoscopic submucosal dissection; APC: argon plasma coagulation; LR: local resection; S/TG: sub/total gastrectomy; PD/PDDD: pancreaticoduodenectomy/pylorus preserving 
pancreaticoduodenectomy; Surv: Endoscopic surveillance; ER: endoscopic resection; SR: surgical resection; ®: multiple tumours; -: data not reported in manuscript; Complications: § Bleeding ¶ perforation ~ abdominal pain # 
anaesthetic complication ¤ wound infection ¥ leak × pancreatic fistula 
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Figure 2 
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Figure 3 
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Figure 4 
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LN positive
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SUPPLEMENTARY DATA 
Literature Search strategy Gastric Neuroendocrine Tumours 
PubMed and Medline databases were interrogated and search results from #23-26 were 
included.  
Table 1 
# Database Search term Results 
1 PubMed (neuroendocrine tumo*r).af 172341 
2 PubMed (carcinoid).af 16848 
3 PubMed (NET).af 261783 
4 PubMed (1 OR 2 OR 3) 433287 
5 PubMed (gastric).af 389478 
6 PubMed (stomach).af 271788 
7 PubMed (5 OR 6) 390741 
8 PubMed (4 AND 7) 8378 
9 PubMed (endoscop*).af 239114 
10 PubMed (endoscopy).af 371044 
11 PubMed (endoscopic).af 423523 
12 PubMed (mucosal resection).af 3704 
13 PubMed (EMR).af 7290 
14 PubMed (submucosal dissection).af 3932 
15 PubMed (ESD).af 4233 
16 PubMed (polypectomy).af 4478 
17 PubMed (endoscopic ultrasound).af 21890 
18 PubMed (endoscopic surveillance).af 1272 
19 PubMed (gastrectomy).af 43076 
20 PubMed (antrectomy).af 948 
21 PubMed (9 OR 10 OR 11) 432584 
22 PubMed (12 OR 13 OR 14 OR 15 OR 16) 18137 
23 PubMed (8 AND 21 AND 22) 211 
24 PubMed (8 AND 17) 180 
25 PubMed (8 AND 18) 33 
26 PubMed (8 AND 19 AND 20) 29 
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Literature Search strategy Duodenal Neuroendocrine Tumours 
 
PubMed and Medline databases were interrogated and search results from #24-27 included.  
Table 2 
# Database Search term Results 
1 PubMed (neuroendocrine tumo*r).ti,ab 173041 
2 PubMed (carcinoid).ti,ab 16885 
3 PubMed (NET).ti,ab 263062 
4 PubMed (1 OR 2 OR 3) 435241 
5 PubMed (duoden*).ti,ab 87941 
6 PubMed (duodenum).ti,ab 64626 
7 PubMed (duodenal).ti,ab 115230 
8 PubMed (5 OR 6 OR 7) 120278 
9 PubMed (4 AND 8) 3138 
10 PubMed (endoscop*).ti,ab 240305 
11 PubMed (endoscopy).ti,ab 372658 
12 PubMed (endoscopic).ti,ab 425423 
13 PubMed (mucosal resection).ti,ab 3763 
14 PubMed (EMR).ti,ab 7390 
15 PubMed (submucosal dissection).ti,ab 3976 
16 PubMed (ESD).ti,ab 4266 
17 PubMed (polypectomy).ti,ab 4502 
18 PubMed (endoscopic ultrasound).ti,ab 22023 
19 PubMed (endoscopic surveillance).ti,ab 1279 
20 PubMed (duodenectomy).ti,ab 648 
21 PubMed (surgery).ti,ab 4530072 
22 PubMed (10 OR 11 OR 12) 434521 
23 PubMed (13 OR 14 OR 15 OR 16 OR 17) 18320 
24 PubMed (9 AND 22 AND 23) 101 
25 PubMed (9 AND 18) 160 
26 PubMed (9 AND 19) 4 
27 PubMed (9 AND 20 AND 21) 39 
 
